Xilio Therapeutics Appoints Christina Rossi to Its Board of Directors

“I am very pleased to welcome Christy to our board of directors during this exciting phase of growth for our company,” said Dan Lynch, chairman of the board of directors of Xilio Therapeutics. “Christy is a leader with a proven track record of shaping corporate strategy and leading companies through various stages of development. As we head toward plans to initiate clinical development of our lead candidates, her unique and forward-looking perspective compliments those of the current board members and will provide important insights to Xilio as we plan for the future.”

Ms. Rossi joins the Xilio board of directors with 20 years of experience in the pharmaceutical and biotechnology industries. She is currently the chief commercial officer of Blueprint Medicines and played a critical role in the U.S. launches of AYVAKIT™ and GAVRETO® in certain genomically defined cancers. Prior to joining Blueprint Medicines, she served in various roles at Sanofi Genzyme, leading the launches of several new multiple sclerosis (MS) therapies, and optimized operations to expand patient access. Ms. Rossi’s positions at Sanofi Genzyme included serving as the MS business unit head of North America; vice president, MS sales; and vice president, MS patient and provider services. Prior to joining Sanofi Genzyme, Ms. Rossi held various roles at Biogen, Inc, leading brands and a biosimilar-focused venture. Ms. Rossi also consulted within the healthcare practice of Boston Consulting Group. Ms. Rossi holds a Bachelor of Science in biology from Duke University and a Master of Business Administration from Harvard Business School.

About Xilio Therapeutics

Xilio Therapeutics is a privately-held biotechnology company that uses its proprietary technology to engineer potent cancer immunotherapies that have the potential to unleash the power of the immune system selectively at the site of the tumor. Xilio has designed its investigational therapies with the goal of maximizing efficacy and overcoming the significant toxicities associated with certain clinically validated immuno-oncology therapies, positioning them as potential treatments for a significant number of patients. The company’s proprietary pipeline includes XTX202, a tumor-selective modified form of IL-2, and XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody (mAb), as well as tumor-selective IL-12 and IL-15 research programs. Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005112/en/